{'52WeekChange': -0.061820626,
 'SandP52WeekChange': 0.0644362,
 'address1': '611 Gateway Boulevard',
 'address2': 'Suite 900',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 13.81,
 'askSize': 3200,
 'averageDailyVolume10Day': 569675,
 'averageVolume': 1626282,
 'averageVolume10days': 569675,
 'beta': 2.336694,
 'beta3Year': None,
 'bid': 13.8,
 'bidSize': 900,
 'bookValue': 4.289,
 'category': None,
 'circulatingSupply': None,
 'city': 'South San Francisco',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 13.99,
 'dayLow': 13.39,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -2.079,
 'enterpriseToRevenue': None,
 'enterpriseValue': 613305728,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 12.797,
 'fiftyTwoWeekHigh': 19.36,
 'fiftyTwoWeekLow': 4.52,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 43240735,
 'forwardEps': -4.08,
 'forwardPE': -3.384804,
 'fromCurrency': None,
 'fullTimeEmployees': 409,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.02456,
 'heldPercentInstitutions': 1.07985,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/atarabio.com',
 'longBusinessSummary': 'Atara Biotherapeutics, Inc., an off-the-shelf T-cell '
                        'immunotherapy company, develops treatments for '
                        'patients with cancer, autoimmune, and viral diseases '
                        'in the United States. It is developing tabelecleucel, '
                        'a T-cell immunotherapy that is Phase III clinical '
                        'trials for the treatment of rituximab-refractory '
                        'epstein-barr virus (EBV) associated post-transplant '
                        'lymphoproliferative disorder, as well as other EBV '
                        'associated hematologic and solid tumors, including '
                        'nasopharyngeal carcinoma. The company is also '
                        'developing next-generation CAR T immunotherapies for '
                        'patients with hematologic malignancies and solid '
                        'tumors, and autoimmune and viral diseases, including '
                        'ATA2271 for mesothelin; ATA2321 for acute myeloid '
                        'leukemia; and ATA2431 and ATA3219 for B-cell '
                        'lymphomas, as well as ATA188 and ATA190 that are in '
                        'Phase I clinical trials for the treatment of multiple '
                        'sclerosis. In addition, it is developing ATA621 '
                        'against the BK and JC viruses; ATA368 for patients '
                        'with human papillomavirus and associated cancers; '
                        'ATA520 to treat Wilms tumor 1; and ATA230 against '
                        'cytomegalovirus and related diseases. The company has '
                        'a license agreement with Memorial Sloan Kettering '
                        'Cancer Center; license, and research and development '
                        'collaboration agreement with QIMR Berghofer Medical '
                        'Research Institute; and strategic collaboration with '
                        'H. Lee Moffitt Cancer Center. Atara Biotherapeutics, '
                        'Inc. was founded in 2012 and is headquartered in '
                        'South San Francisco, California.',
 'longName': 'Atara Biotherapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 1020698432,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_248196818',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -298228000,
 'nextFiscalYearEnd': 1640908800,
 'open': 13.92,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '650 278 8930',
 'previousClose': 13.97,
 'priceHint': 2,
 'priceToBook': 3.2198648,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 13.99,
 'regularMarketDayLow': 13.39,
 'regularMarketOpen': 13.92,
 'regularMarketPreviousClose': 13.97,
 'regularMarketPrice': 13.92,
 'regularMarketVolume': 555232,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 73910096,
 'sharesPercentSharesOut': 0.1834,
 'sharesShort': 13558513,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 11868405,
 'shortName': 'Atara Biotherapeutics, Inc.',
 'shortPercentOfFloat': 0.2134,
 'shortRatio': 7.91,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'ATRA',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -5.415,
 'twoHundredDayAverage': 11.638381,
 'volume': 555232,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.atarabio.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94080'}